Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial - PubMed

Affiliations

• PMID: 17363489
• DOI: 10.1158/1535-7163.MCT-06-0552

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Huw D Thomas et al. Mol Cancer Ther. 2007 Mar.

Abstract

Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks. Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation. Our aim was to identify a PARP inhibitor for clinical trial from a panel of 42 potent PARP inhibitors (K(i), 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures. We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts. Excellent chemopotentiation and radiopotentiation were observed in vitro, with 17 of the compounds causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compounds were more potent radiosensitizers than AG14361. In tumor-bearing mice, none of the compounds were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity. Compounds that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen. These studies have identified a compound, AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361. The phosphate salt of AG14447 (AG014699), which has improved aqueous solubility, has been selected for clinical trial.

Similar articles

• Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

  Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ. Calabrese CR, et al. J Natl Cancer Inst. 2004 Jan 7;96(1):56-67. doi: 10.1093/jnci/djh005. J Natl Cancer Inst. 2004. PMID: 14709739

• Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

  Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, Skalitzky D, Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ. Calabrese CR, et al. Clin Cancer Res. 2003 Jul;9(7):2711-8. Clin Cancer Res. 2003. PMID: 12855651

• Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

  Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z, Newell DR. Curtin NJ, et al. Clin Cancer Res. 2004 Feb 1;10(3):881-9. doi: 10.1158/1078-0432.ccr-1144-3. Clin Cancer Res. 2004. PMID: 14871963

• PARP inhibitors for cancer therapy.

  Curtin NJ. Curtin NJ. Expert Rev Mol Med. 2005 Mar 15;7(4):1-20. doi: 10.1017/S146239940500904X. Expert Rev Mol Med. 2005. PMID: 15836799 Review.

• Chemopotentiation by PARP inhibitors in cancer therapy.

  Tentori L, Graziani G. Tentori L, et al. Pharmacol Res. 2005 Jul;52(1):25-33. doi: 10.1016/j.phrs.2005.02.010. Pharmacol Res. 2005. PMID: 15911331 Review.

Cited by

• Evidence for tankyrases as antineoplastic targets in lung cancer.

  Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ. Busch AM, et al. BMC Cancer. 2013 Apr 28;13:211. doi: 10.1186/1471-2407-13-211. BMC Cancer. 2013. PMID: 23621985 Free PMC article.

• Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

  Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, Kaufmann SH. Patel AG, et al. J Biol Chem. 2012 Feb 3;287(6):4198-210. doi: 10.1074/jbc.M111.296475. Epub 2011 Dec 12. J Biol Chem. 2012. PMID: 22158865 Free PMC article.

• Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.

  Xiao JJ, Nowak D, Ramlau R, Tomaszewska-Kiecana M, Wysocki PJ, Isaacson J, Beltman J, Nash E, Kaczanowski R, Arold G, Watkins S. Xiao JJ, et al. Clin Transl Sci. 2019 Jan;12(1):58-65. doi: 10.1111/cts.12600. Epub 2018 Dec 20. Clin Transl Sci. 2019. PMID: 30427584 Free PMC article. Clinical Trial.

• Integrating biologically targeted therapy in head and neck squamous cell carcinomas.

  Le QT, Raben D. Le QT, et al. Semin Radiat Oncol. 2009 Jan;19(1):53-62. doi: 10.1016/j.semradonc.2008.09.010. Semin Radiat Oncol. 2009. PMID: 19028346 Free PMC article. Review.

• Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma.

  Zhang X, Wang L, Chen S, Huang P, Ma L, Ding H, Basappa B, Zhu T, Lobie PE, Pandey V. Zhang X, et al. Commun Med (Lond). 2022 Jul 2;2:82. doi: 10.1038/s43856-022-00142-3. eCollection 2022. Commun Med (Lond). 2022. PMID: 35791346 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Guide to Pharmacology

• Miscellaneous

  • NCI CPTAC Assay Portal